Form 4: Zenas BioPharma CEO Leon Moulder Jr. Granted 400,000 Stock Options

Zenas BioPharma's Chief Executive Officer and Director, Leon O. Moulder Jr., was granted 400,000 stock options with an exercise price of $11.94, vesting over a four-year period.

Summary

• Leon O. Moulder Jr., the Chief Executive Officer and a Director of Zenas BioPharma, Inc. (ZBIO), reported the acquisition of 400,000 stock options.
• The stock options have an exercise price of $11.94 per share.
• The options will vest as to 25% of the underlying shares on June 10, 2026, which is the first anniversary of the vesting commencement date.
• The remaining shares will vest in equal monthly installments over 36 months thereafter, contingent upon Mr. Moulder's continued service to the company.
• The expiration date for these stock options is June 10, 2035.

Sentiment

Score: 7

Explanation: The sentiment is generally positive as it represents a standard and incentivizing executive compensation event, aligning management's interests with long-term company performance. It is not a direct operational or financial achievement but a structural positive.

Positives

• The grant of stock options aligns the Chief Executive Officer's long-term financial interests with the performance of Zenas BioPharma's stock and shareholder value creation.
• This is a standard practice in executive compensation, designed to incentivize leadership to drive company growth and profitability.

Negatives

• The value of the stock options is dependent on the future performance of Zenas BioPharma's stock price, meaning there is no guaranteed value until exercised and sold.
• The options are subject to a vesting schedule, requiring continued service, which means they are not immediately liquid or fully owned.

Risks

• The value of the stock options could be negatively impacted if Zenas BioPharma's stock price declines below the exercise price of $11.94.
• The options may be forfeited if the CEO's service to the company ceases before the vesting schedule is complete.

Future Outlook

The grant of stock options serves as a long-term incentive for the CEO, aligning his financial interests with the future growth and success of Zenas BioPharma over the multi-year vesting period, thereby encouraging strategic decisions that enhance shareholder value.

Management Comments

• Leon O. Moulder Jr. is identified as the Chief Executive Officer of Zenas BioPharma, Inc.

Industry Context

The granting of stock options to executive leadership is a common and widely accepted practice within the biotechnology and pharmaceutical industries, serving as a key component of executive compensation packages designed to attract, retain, and motivate top talent.

Comparison to Industry Standards

• This type of equity grant is a standard form of executive compensation in the biotechnology sector, aiming to align management incentives with long-term shareholder value creation.
• The specific size of the 400,000 option grant would typically be evaluated against grants made to CEOs at peer companies of similar market capitalization, stage of development, and industry focus (e.g., other clinical-stage biopharmaceutical companies) to determine its relative competitiveness and scale, though such comparative data is not provided in this filing.

Related Party Transactions

• The grant of stock options to Leon O. Moulder Jr., the CEO and a Director, constitutes a related party transaction, which is a standard form of executive compensation.

Stakeholder Impact

• Shareholders: The grant aims to align the CEO's interests with long-term shareholder value creation, potentially leading to improved company performance.
• Employees: No direct impact on general employees is mentioned in this filing.

Next Steps

• Continued service by Leon O. Moulder Jr. to ensure the vesting of the granted stock options according to the specified schedule.

Key Dates

Recommendation

Keywords

Zenas BioPharma, ZBIO, Stock Options, Executive Compensation, Form 4, Insider Transaction, Equity Grant, CEO Compensation